CClinicalTrials.gg
Status unknownNCT04181086Updated Nov 29, 2019

Pattern and Management of Intracranial Cavernoma

An observational study in Management of Intracranial Cavernous Hemangioma, sponsored by Assiut University. Status unknown. Per ClinicalTrials.gov, last updated 2019-11-29.

Sponsored by Assiut University · Observational

The sponsor has not verified this record recently (last verified Nov 2019), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
35
Sex
All
01

Study summary

Intracranial cavernous vascular malformations are variously known as cavernous angiomas, cavernous hemangiomas, or, more simply, cavernomas. Cavernomas are congenital low flow vascular lesions. It composed of irregular sinusoidal vascular channels, lacking smooth muscle, and elastic fibers. They lack feeding arteries or draining veins and contain no neural tissue. The first description of an intracranial cavernoma was given by Virchow, in 1863. For over a century, it was considered to be an extremely rare malformation, usually found at autopsy, and exceptionally diagnosed during life. The prevalence of cerebral cavernous malformations (CCM) is estimated to be 0.4-0.9%.

02

Conditions studied

  • Management of Intracranial Cavernous Hemangioma

Browse trials for

03

In context

Hemangioma

141 studies on the registry are indexed under Hemangioma; 16 are open to participants now.

This study's planned enrollment of 35 is below the median of 79 across 56 observational studies indexed under Hemangioma.

Browse Hemangioma studies →

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

all patients with confirmed diagnosis of intracranial cavernoma with MRI and will undergo surgery

Inclusion criteria

  • All patients presented with intracranial cavernomas (single or multiple, superficial or deep, supratentorial or infratentorial)
  • Denovo or recurrent patients.

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
35 participants (estimated)
Patient registry
No

Interventions

  • Proceduresurgical excision of intracranial cavernoma

    microvascular excision of intracranial cavernoma

06

What researchers measure

Primary outcomes

  1. clinical outcome

    Measured by Modified Rankin Scale Measures the degree of disability or dependence in the daily activities of people who have suffered any cause of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms. 1. - No significant disability. Able to carry out all usual activities, despite some symptoms. 2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3. - Moderate disability. Requires some help, but able to walk unassisted. 4. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. - Dead.

    Time frame: one month post operative

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04181086
Lead sponsor
Assiut University
Responsible party
Moataz Elshenawi (assistant lecturer, Assiut University) — Principal investigator
First posted
Nov 29, 2019
Start date
Jan 1, 2020 (estimated)
Primary completion
Jun 1, 2021 (estimated)
Completion
Jan 1, 2022 (estimated)
Last update
Nov 29, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion